PowerVision Inc. announced the first 10 patients have received lens implants in its multicenter clinical study assessing the performance of its fluid-based accommodating intraocular lens in cataract patients.
The planned enrollment in this study is 115 participants undergoing cataract surgery.
The PowerVision press release stated that the first 10 patients received their implants at three eye centers in South Africa; four sites in Germany are also participating in the study and will begin enrolling patients later in 2014.
This study will form the basis for PowerVision’s CE marking of the FluidVision lens in the European Union, which is expected to occur sometime next year, according to the press release.
The FluidVision lens, PowerVision’s fluid-controlled accommodating IOL, contains fluid inside the lens that moves in response to the natural muscle forces in the eye.
The press release further explained that the FluidVision lens provides true accommodation by mimicking the eye’s natural accommodative process, becoming thicker when the patient needs to see up close or thinner when he or she needs to see far away.
PowerVision’s President and CEO Barry Cheskin said that they expect to complete patient enrollment this year and to receive the CE Mark sometime in 2015.